Price$21.61+0.16 (+0.77%)
01:30 PM07:45 PM
News · 26 weeks59+175%
2026-03-012026-08-23
Mix3190d
- Insider16(52%)
- Analyst6(19%)
- Other3(10%)
- SEC Filings3(10%)
- Earnings2(6%)
- Leadership1(3%)
Latest news
25 items- PRPROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026SAN JOSE, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced members of management will present and host investor meetings at the upcoming Baird 2026 Global Healthcare Conference in New York City on Tuesday, September 15. To view the presentation or schedule a meeting with management, please reach out to your Baird representative. About PROCEPT BioRobotics CorporationPROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Com
- INSIDEREVP, Chief Technology Officer Templin Barry L was granted 26,246 shares, increasing direct ownership by 38% to 95,199 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDEREVP, CLO, CORP. SEC. Nouri Alaleh was granted 22,965 shares, increasing direct ownership by 22% to 128,034 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDEREVP, CFO Waters Kevin was granted 29,527 shares, increasing direct ownership by 20% to 180,728 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERChief Strat/Marketing Officer Sharma Pooja was granted 23,622 shares, increasing direct ownership by 27% to 111,181 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERPresident, CEO Wood Larry L bought $498,315 worth of shares (23,900 units at $20.85) (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- SECSEC Form 10-Q filed by PROCEPT BioRobotics Corporation10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)
- ANALYSTPROCEPT BioRobotics downgraded by William BlairWilliam Blair downgraded PROCEPT BioRobotics from Outperform to Mkt Perform
- ANALYSTPROCEPT BioRobotics downgraded by Wells Fargo with a new price targetWells Fargo downgraded PROCEPT BioRobotics from Overweight to Equal Weight and set a new price target of $19.00
- SECPROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
- PRPROCEPT BioRobotics Reports Second Quarter 2026 Financial ResultsSAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2026. "This was an important quarter for PROCEPT as we continued to strengthen the foundation of our business for long-term growth," said Larry Wood, Chief Executive Officer. "We delivered 19% revenue growth, achieved record HYDROS placements, demonstrated continued pricing discipline, executed a more robust replacement strategy and completed the commercial realignment that positions us to e
- ANALYSTPROCEPT BioRobotics downgraded by UBS with a new price targetUBS downgraded PROCEPT BioRobotics from Buy to Neutral and set a new price target of $20.00
- PRMobia Medical Appoints Reza Zadno, Ph.D., to its Board of DirectorsAUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (NASDAQ:MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee. "We are pleased to welcome Reza to the Mobia Medical Board of Directors," said Richard Foust, President and Chief Executive Officer of Mobia Medical. "He has built and scaled multiple public medical technology companies, and his operational perspective and public company governance experience wi
- PRPROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/8fznodv2 Dial-in registration for sell-side research ana
- ANALYSTPROCEPT BioRobotics downgraded by Truist with a new price targetTruist downgraded PROCEPT BioRobotics from Buy to Hold and set a new price target of $25.00
- ANALYSTEvercore ISI initiated coverage on PROCEPT BioRobotics with a new price targetEvercore ISI initiated coverage of PROCEPT BioRobotics with a rating of Outperform and set a new price target of $30.00
- ANALYSTPROCEPT BioRobotics downgraded by Leerink Partners with a new price targetLeerink Partners downgraded PROCEPT BioRobotics from Outperform to Market Perform and set a new price target of $29.00
- INSIDERDirector Desai Antal Rohit was granted 3,315 shares, increasing direct ownership by 9% to 38,467 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Dodrill Amy M. was granted 3,315 shares, increasing direct ownership by 43% to 10,941 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Garrett Mary was granted 3,315 shares, increasing direct ownership by 23% to 17,700 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Harris Taylor C. was granted 3,315 shares, increasing direct ownership by 3% to 102,491 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Little Elisabeth Sandoval was granted 3,315 shares, increasing direct ownership by 26% to 15,876 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Moll Frederic H was granted 3,315 shares, increasing direct ownership by 0.38% to 866,474 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Prescott Thomas M was granted 3,315 shares, increasing direct ownership by 85% to 7,211 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Puckett Dan was granted 3,315 shares, increasing direct ownership by 61% to 8,791 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
PRCT FAQ
7 questionsWhat does PROCEPT BioRobotics Corporation do?
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.Where does PRCT stock trade?
PROCEPT BioRobotics Corporation (PRCT) is listed on NASDAQ.What sector and industry is PRCT in?
PROCEPT BioRobotics Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did PROCEPT BioRobotics Corporation go public?
PROCEPT BioRobotics Corporation (PRCT) completed its IPO in 2021.What are analysts saying about PRCT?
PROCEPT BioRobotics Corporation has had 8 recent analyst actions on file. The most recent action was from William Blair: Mkt Perform on 2026-08-05. Recent price targets range from $1900.00 to $3000.00.What companies are similar to PRCT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare PRCT side-by-side with any of them on Quantisnow.How can I track PRCT on Quantisnow?
Quantisnow aggregates PROCEPT BioRobotics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRCT to receive live email and push alerts on every new disclosure.